Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial

Melissa L. Abel, Nobuyuki Takahashi, Cody Peer, Christophe E. Redon, Samantha Nichols, Rasa Vilimas, Min Jung Lee, Sunmin Lee, Meenakshi Shelat, Robbie Kattappuram, Linda Sciuto, Danielle Pinkiert, Chante Graham, Donna Butcher, Baktiar Karim, Ajit Kumar Sharma, Justin Malin, Rajesh Kumar, Christopher W. Schultz, Shubhank GoyalJaydira del Rivero, Manan Krishnamurthy, Deep Upadhyay, Brett Schroeder, Tristan Sissung, Manoj Tyagi, Jung Kim, Yves Pommier, Mirit Aladjem, Mark Raffeld, William Douglas Figg, Jane Trepel, Liqiang Xi, Parth Desai, Anish Thomas*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Purpose: Despite promising preclinical studies, toxicities have precluded combinationsofchemotherapy andDNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations. Patients and Methods: In a phase I trial, we combined sacituzumab govitecan, antibody–drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib. Twelve patients were enrolled across three dose levels. Results: Treatment was well tolerated, with improved safety over conventional chemotherapy-based combinations, allowing escalation to the highest dose. No dose-limiting toxicities or clinically relevant ≥grade 4 adverse events occurred. Tumor regressions were observed in 2 patients with neuroendocrine prostate cancer, and a patient with small cell lung cancer transformed from EGFR-mutant non–small cell lung cancer. Conclusions: ADC-based delivery of cytotoxic payloads represents a new paradigm to increase efficacy of DDR inhibitors.

Original languageEnglish
Pages (from-to)OF1-OF9
JournalClinical Cancer Research
Volume29
Issue number18
DOIs
StatePublished - 15 Sep 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial'. Together they form a unique fingerprint.

Cite this